Santhera Pharmaceuticals Holding AG

Swiss Stock Exchange:SANN.SW

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Switzerland

Market Cap

USD 185.53 M

Share Price

USD 14.42

Avg Daily Volume

46,910

Change (1 day)

0.35%

Change (1 year)

34.27%

Change (YTD)

-5.64%

Santhera Pharmaceuticals Holding AG Net Income Margin for the year ending December 31, 2024: -107.30%

Santhera Pharmaceuticals Holding AG Net Income Margin is -107.30% for the year ending December 31, 2024, a -302.56% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Santhera Pharmaceuticals Holding AG Net Income Margin for the year ending December 31, 2023 was 52.97%, a -105.57% change year over year.
Santhera Pharmaceuticals Holding AG Net Income Margin for the year ending December 31, 2022 was -951.10%.
Santhera Pharmaceuticals Holding AG Net Income Margin for the year ending December 31, 2020 was -450.82%, a 1,691.02% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income Margin	EBT Margin	Operating Income Margin	Gross Profit Margin

Swiss Stock Exchange: SANN.SW

Santhera Pharmaceuticals Holding AG

CEO	Mr. Dario Eklund
IPO Date	Nov. 3, 2006
Location	Switzerland
Headquarters	Hohenrainstrasse 24
Employees	78
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.